1 year ago

Work programme 2017


Drivers The global

Drivers The global nature of medicines development and research continues to be a key driver of the Agency's international collaborative activities. The increasing complexity of supply chains, combined with everexpanding manufacture outside the EU, presents additional oversight challenges, increasing risks of falsification and concerns about data integrity. At the same time, the similarity of tasks and objectives of regulators worldwide leads to increasing awareness of the need to avoid duplication and use global regulatory resources more effectively. As a result, and particularly in resource-limited settings, there is enhanced willingness for regulators to work collaboratively, and the EU regulatory network is seen as an effective model. Realisation of the need for greater strategic oversight and common international approaches to the protection of public health requires mechanisms to build greater trust and confidence in other regulatory systems. To achieve this, an international coalition of medicines regulatory authorities (ICMRA) is being established, to which the Agency contributes through its active membership and support for the virtual secretariat. Reforms to ICH – now called the International Council for Harmonization – came fully into force in 2016, allowing for a broader global membership and strengthening ICH as the leading platform for global pharmaceutical regulatory harmonisation. VICH is subject to an updated strategy and a particular focus will be to foster the VICH Outreach programme, which aims to extend uptake of VICH guidelines to countries throughout the world with less developed regulatory systems. The Agency plays an important role in supporting the European Commission by coordinating the EU expertise and contribution to the work of ICH and VICH. Alongside enhanced cooperation in the field of inspections and supply-chain continuity, the Agency will additionally support efforts to increase international work-sharing in these and other areas, as well as support convergence of international practices and work within international organisations to encourage better and more effective use of global regulatory resources. The Ebola and Zika outbreaks exemplified the need to support the strengthening of regulatory systems to protect global public health, as set out in the 2014 World Health Assembly resolution WHA67.20. The EMA contributes to the WHO work on regulatory-systems strengthening, including through its activities within the Article 58 framework and a pilot programme on collaborative registration of medicines in resource-constrained countries. Workload indicators Results Forecasts 2014 2015 2016 2017 n/a Performance indicators Results Targets 2014 2015 2016 2017 n/a Work programme 2017 EMA/583016/2016 Page 94/123

Additional objectives and activities Medium-term objective MAWP initiative Activity description Timeframe Start End Ensure best use of resources through promoting mutual reliance and work-sharing Promote convergence of global standards and contribution to international fora Improve application of equivalent standards of good manufacturing and clinical practices throughout the world Assure product supply chain and data integrity Support training and capacity building of non-EU regulators 4.3-3 Implement and review the IGDRP Before 2017 information-sharing pilot to the centralised procedure 2016 Optimise Article 58 scientific opinion activities, including enhance collaboration with WHO and concerned regulators and develop additional communication tools 2015 ongoing Provide assistance to candidate countries, to 2016 2018 align their standards and practices with those established in the European Union and to further foster their integration process 1.1-4 Finalise the guideline on dementia 2016 2018 Contribute to global dementia 2016 2018 activities/programme in collaboration with other partner agencies, the EC and international organisations 4.2-2 Enhance mechanisms to facilitate local Ongoing ongoing observers' participation in inspections carried out in non-EU countries 4.1-1 Promote increased international cooperation Ongoing ongoing in the area of supply chain security in particular through efforts to coordinate and integrate initiatives at the level of ICMRA 4.4-2 Increase the number of opportunities for non- 2016 ongoing EU regulators, in particular those of candidate and potential candidate countries, to participate in scientific and regulatory training activities Explore and foster opportunities for the EU 2017 ongoing Network to contribute to scientific and regulatory training events organised outside the EU In collaboration with the WHO, increase non- EU regulators' awareness of scientific and regulatory training opportunities offered by the EU Network through the WHO training platform 2016 ongoing Resources 2017 Financial resources (cost, thousand Euro) 3,844 Work programme 2017 EMA/583016/2016 Page 95/123

2017 Work Programme
MHRA powerpoint template - TOPRA
Work Programme 2013 - ECHA - Europa
The 9th TOPRA Annual Symposium 2012 - Human Medicines
Work Programme 2011 - ERA - Europa
Monaco 2010 - Drug Information Association
programme activities - European Consortium for Ocean Research ...
The Case of ESA's General Support Technology Programme (GSTP)
VMGN 11 - Veterinary Medicines Directorate - Defra
Aeronautics and Air Transport Research 7th Framework Programme ...
IFAH-Europe annual report 2006 - Bundesverband für Tiergesundheit
How TOPRA in Spain will work - presentation